Todate, these trials are evaluating the effects Smo antagonists developed by multiplepharmaceutical companies in a broad spectrum of cancers, such as BCC, multiple myeloma,brain, breast and gastric cancers. This evidence concerns the gene SMO and skin basal cell carcinoma.